Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2C8H14NO3.Ca |
| Molecular Weight | 384.481 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Ca++].CC(=O)NCCCCCC([O-])=O.CC(=O)NCCCCCC([O-])=O
InChI
InChIKey=SBWAKKRVPRVVTI-UHFFFAOYSA-L
InChI=1S/2C8H15NO3.Ca/c2*1-7(10)9-6-4-2-3-5-8(11)12;/h2*2-6H2,1H3,(H,9,10)(H,11,12);/q;;+2/p-2
DescriptionCurator's Comment: The description was created based on several sources, including
https://www.drugs.com/international/acexamic-acid.html | https://www.ncbi.nlm.nih.gov/pubmed/18353035 | https://www.ncbi.nlm.nih.gov/pubmed/6159453 | https://www.ncbi.nlm.nih.gov/pubmed/19470000
Curator's Comment: The description was created based on several sources, including
https://www.drugs.com/international/acexamic-acid.html | https://www.ncbi.nlm.nih.gov/pubmed/18353035 | https://www.ncbi.nlm.nih.gov/pubmed/6159453 | https://www.ncbi.nlm.nih.gov/pubmed/19470000
Acexamic acid (N-acetyl-amino-6-hexanoic acid) is a drug used as a cicatrization helper. Some studies show that the acexamic acid prevents the formation the connective inflamed tissue and enables its healing. The association from acexamic acid with zinc, zinc acexamate, has been used in the treatment of gastric and duodenal ulcer and in the prevention of gastric ulcer induced by nonsteroidal anti-inflammatory drugs.
Originator
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Acemin ointment Approved UseLong-lasting non-healing wounds, skin and mucous burns, chronic traumatic osteomyelitis, closed and long-lasting incomplete fractures of bones, prevention of hyper-scarring, acceleration of the formation of a postoperative cosmetic scar, acceleration of engraftment of auto- and homotransplants. |
|||
| Curative | Acemin ointment Approved UseLong-lasting non-healing wounds, skin and mucous burns, chronic traumatic osteomyelitis, closed and long-lasting incomplete fractures of bones, prevention of hyper-scarring, acceleration of the formation of a postoperative cosmetic scar, acceleration of engraftment of auto- and homotransplants. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Increase in bone growth factors with healing rat fractures: the enhancing effect of zinc. | 2001 Oct |
|
| Alteration in serum and bone component findings induced in streptozotocin-diabetic rats is restored by zinc acexamate. | 2003 Dec |
|
| Great increase in bone 66 kDa protein and osteocalcin at later stages with healing rat fractures: effect of zinc treatment. | 2003 Feb |
|
| Enhancement of albumin expression in bone tissues with healing rat fractures. | 2003 May 15 |
|
| Preventive effect of zinc acexamate administration in streptozotocin-diabetic rats: Restoration of bone loss. | 2003 Nov |
|
| Topical treatment of peritoneal catheter-related exit-site granuloma with acetamidohexanoic acid combined with gentamicin. | 2006 Jul-Aug |
|
| Pharmacokinetics and first-pass effects of epsilon-acetamidocaproic acid after administration of zinc acexamate in rats. | 2010 Jul |
|
| Influence of cyclodextrin complexation with NSAIDs on NSAID/cold stress-induced gastric ulceration in rats. | 2010 Jul 5 |
|
| Performance of human immunostimulating agents in the improvement of fish cytogenetic preparations. | 2010 Sep 14 |
Patents
Sample Use Guides
Outer: 5% ointment is applied to the disinfected wound surface daily. The course of treatment is from 10 to 30 days.
Route of Administration:
Topical
The mouse fibroblast cell line (NCTC Clone L 929) was maintained as stock culture in a minimum essential medium (MEM) supplemented with 10% calf serum and 200 i.u./ml G penicillin and 100 pg/d streptomycin. Cultures for growth studies were established by inoculating 7 X l0^4 cells in 2 ml medium in 35-mm plastic tissue culture dishes. They were maintained for 24 h to obtain a good attachment, then incubated in 5% calf serum medium supplemented or not with the drugs tested. Acexamic acid increased the growth rate of L 929 when used at a concentration of 0.001%
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB00279MIG
Created by
admin on Fri Dec 15 15:10:54 GMT 2023 , Edited by admin on Fri Dec 15 15:10:54 GMT 2023
|
PRIMARY | |||
|
253-010-4
Created by
admin on Fri Dec 15 15:10:54 GMT 2023 , Edited by admin on Fri Dec 15 15:10:54 GMT 2023
|
PRIMARY | |||
|
168217
Created by
admin on Fri Dec 15 15:10:54 GMT 2023 , Edited by admin on Fri Dec 15 15:10:54 GMT 2023
|
PRIMARY | |||
|
9886373
Created by
admin on Fri Dec 15 15:10:54 GMT 2023 , Edited by admin on Fri Dec 15 15:10:54 GMT 2023
|
PRIMARY | |||
|
36392-66-2
Created by
admin on Fri Dec 15 15:10:54 GMT 2023 , Edited by admin on Fri Dec 15 15:10:54 GMT 2023
|
PRIMARY | |||
|
100000078830
Created by
admin on Fri Dec 15 15:10:54 GMT 2023 , Edited by admin on Fri Dec 15 15:10:54 GMT 2023
|
PRIMARY | |||
|
3DHV2K82D1
Created by
admin on Fri Dec 15 15:10:54 GMT 2023 , Edited by admin on Fri Dec 15 15:10:54 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
